Real-world impact of rotavirus vaccination

Pediatric Infectious Disease Journal

Volumn 30, Issue SUPPL. 1, 2011, Pages

  Patel, Manish M ^a   Steele, Duncan ^b   Gentsch, Jon R ^a   Wecker, John ^b   Glass, Roger I ^a   Parashar, Umesh D ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b PATH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN VP4; PROTEIN VP7; ROTAVIRUS VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; DISEASE SURVEILLANCE; DRUG EFFICACY; HERD IMMUNITY; HUMAN; HUMAN ROTAVIRUS; INFECTION PREVENTION; INFECTIOUS DIARRHEA; MASS IMMUNIZATION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; ROTAVIRUS INFECTION; SEASONAL VARIATION; SEROTYPE; VIRUS STRAIN;

AMERICAS; AUSTRALIA; EUROPE; GASTROENTERITIS; GENOTYPE; HUMANS; IMMUNITY, HERD; ROTAVIRUS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SEASONS; VACCINATION;

EID: 78751520530     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181fefa1f     Document Type: Article

References (48)

1. Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet. 2010;375: 1969-1987.
2. Parashar UD, Burton A, Lanata C, et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis. 2009;200(suppl 1): S9-S15.
3. WHO. Meeting of the strategic advisory group of experts on immunization, October 2009-conclusions and recommendations. Wkly Epidemiol Rec. 2009;84:518.
4. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23-33. (Pubitemid 43048948)
5. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet. 2007; 370:1757-1763.
6. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11-22.
7. Linhares AC, Velazquez FR, Perez-Schael I, et al. Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet. 2008;371:1181-1189.
8. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 376:615-623.
9. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362:289-298.
10. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 376:606-614.
11. WHO. Generic protocol for monitoring impact of rotavirus vaccination on rotavirus disease burden and viral strains. Geneva: WHO; 2009:1-73. Document WHO/IVB/0816.
12. Patel MM, Parashar UD. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. J Infect Dis. 2009;200(suppl 1):S291-S299.
13. Tate JE, Panozzo CA, Payne DC, et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics. 2009;124:465-471.
14. Curns AT, Steiner CA, Barrett M, et al. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis. 2010;201:1617-1624.
15. Yen CY, Guardado JA, Alberto P, et al. Decline in Rotavirus Hospitalizations and Health Care Visits for Diarrhea among Children 5 years of age following implementation of rotavirus vaccination in El salvador Pediatr Infect Dis 2001, 1, 30, S6-S10
16. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med. 2010;362:299-305.
17. Quintanar-Solares M, Yen CY, Esparza-Aguilar M, et al. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children 5 years of age in Mexico Pediatr Infect Dis 2011, 30, S11-S15.
18. Molto Y, Cortes JE, de Oliveira LH, et al.Reduction of diarrhea-associated hospitalizations among children aged 5 years in Panama following the introduction of rotavirus vaccine. Pediatr Infect Dis. 2011;30:S16 -S20.
19. Braeckman T, Van Herck K, Raes M, et al. Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis. 2011;30:S21-S24.
20. Buttery JP, Lambert SB, Grimwood K, et al. Reduction in Rotavirus-associated Acute Gastroenteritis Following Introduction of Rotavirus Vaccine Into Australia's National Childhood Vaccine Schedule. Pediatr Infect Dis. 2011;30:S25-S29.
21. Anderson RM, May RM. Immunisation and herd immunity. Lancet. 1990; 335:641-645.
22. Tate J, Cortese M, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States-review of the first 3 years of post-licensure data. Pediatr Infect Dis. 2011;30:S56-S60.
23. Velazquez FR, Matson DO, Calva JJ, et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med. 1996;335:1022-1028.
24. Estes MK, Kapikian A. Rotaviruses. In: Knipe DM, Howley PM, Griffin DE, et al, eds. Fields Virology. 5th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007:1917-1974.
25. Anderson EJ, Weber SG. Rotavirus infection in adults. Lancet Infect Dis. 2004;4:91-99.
26. Vesikari T, Itzler R, Karvonen A, et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine. 2009;28: 345-351.
27. de Palma O, Cruz L, Ramos H, et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ. 2010;340:c2825.
28. Patel M, Pedreira C, De Oliveira LH, et al. Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA. 2009;301:2243-2251.
29. Torok TJ, Kilgore PE, Clarke MJ, et al. Visualizing geographic and temporal trends in rotavirus activity in the United States, 1991 to 1996. National respiratory and enteric virus surveillance system collaborating laboratories. Pediatr Infect Dis J. 1997;16:941-946.
30. Turcios RM, Curns AT, Holman RC, et al. Temporal and geographic trends of rotavirus activity in the United States, 1997-2004. Pediatr Infect Dis J. 2006;25:451-454.
31. Curns AT, Panozzo CA, Tate J, et al. Remarkable post-vaccination spatio-temporal changes in United States rotavirus activity. Pediatr Infect Dis. 2011;30:S54-S55.
32. Pitzer VE, Viboud C, Simonsen L, et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science. 2009;325:290-294.
33. Jiang V, Jiang B, Tate J, et al. Performance of rotavirus vaccines in developed and developing countries. Hum Vaccin. 2010;6.
34. Perez-Schael I, Garcia D, Gonzalez M, et al. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. J Med Virol. 1990;30:219-229.
35. Perez-Schael I, Guntinas MJ, Perez M, et al. Efficacy of the rhesus rotavirus-based quadrivalent vaccine in infants and young children in Venezuela. N Engl J Med. 1997;337:1181-1187.
36. Gentsch JR, Laird AR, Bielfelt B, et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis. 2005;192(suppl 1):S146-S159.
37. Matthijnssens J, Bilcke J, Ciarlet M, et al. Rotavirus disease and vaccination: impact on genotype diversity. Future Microbiol. 2009;4: 1303-1316.
38. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol. 2005;15:29-56.
39. Nakagomi O, Oyamada H, Kuroki S, et al. Molecular identification of a novel human rotavirus in relation to subgroup and electropherotype of genomic RNA. J Med Virol. 1989;28:163-168.
40. Bernstein DI, Ward RL. Rotarix: development of a live attenuated monovalent human rotavirus vaccine. Pediatr Ann. 2006;35:38-43.
41. Correia JB, Patel MM, Nakagomi O, et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis. 2010;201:363-369.
42. Snelling TL, Andrews RM, Kirkwood CD, et al. Evaluation of the Monovalent human rotavirus vaccine RIX4414 following a G2P[4] outbreak [abstract]. Presented at: The 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 12-15, 2009; San Francisco, CA.
43. Boom JA, Tate JE, Sahni LC, et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics. 2010;125:e199-e207.
44. Carvalho-Costa FA, Volotao E, Santos de Assis RM, et al. Laboratory-based rotavirus surveillance during the introduction of a vaccination program, Brazil, 2005-2009. Pediatr Infect Dis. 2011;30:S35-S41.
45. Hull JJ, Teel E, Kerin T, et al. United States rotavirus surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr Infect Dis. 2011;30:S42-S47.
46. Kirkwood C, Boniface K, Barnes GL, et al. Distribution of Rotavirus Genotypes after introduction of rotavirus vaccines, Rotarix and RotaTeq into the national immunization program of Australia. Pediatr Infect Dis. 2011;30:S48-S53.
47. Field EJ, Vally H, Grimwood K, et al. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics. 2010; 126:e506-e512.
48. Matthijnssens J, Heylen E, Zeller M, et al. Phylodynamic analyses of rotavirus genotypes G9 and G12 underscore their potential for swift global spread. Mol Biol Evol. 2010;27:2431-2436.